MENU

VRNA Stock Verona Pharma plc (VRNA, $41.42) entered Uptrend as Momentum indicator ascends above 0 level on Dec 13, 2024

A.I.dvisor
at Tickeron.com
Loading...
VRNA - Verona Pharma plc
Momentum signal
Bullish Trend
Odds of UP Trend
Tickeron
Momentum signal
Price: $41.42
Daily change: +$2.16 (+5.5%)
Daily volume: 1.2M
Capitalization: $3.4B
Industry: Biotechnology
This indicator may be signaling that VRNA's price has momentum to move higher, since its current price exceeds the price logged 14 days ago. Traders may consider buying the stock or exploring call options. A.I.dvisor backtested 92 similar cases where VRNA's Momentum Indicator exceeded 0, and of them led to a successful outcome. Odds of Success:

Aroon Indicator for VRNA shows an upward move is likely

VRNA's Aroon Indicator triggered a bullish signal on December 10, 2024. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 161 similar instances where the Aroon Indicator showed a similar pattern. In of the 161 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on December 13, 2024. You may want to consider a long position or call options on VRNA as a result. In of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for VRNA just turned positive on December 16, 2024. Looking at past instances where VRNA's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where VRNA advanced for three days, in of 280 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 51 cases where VRNA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VRNA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

VRNA broke above its upper Bollinger Band on December 13, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. VRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (26.110) is normal, around the industry mean (14.626). P/E Ratio (0.000) is within average values for comparable stocks, (87.424). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.836). VRNA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (588.235) is also within normal values, averaging (260.938).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
VRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a r&d company for the treatment of allergic rhinitis and other chronic respiratory diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
3 More London Riverside
Phone
+44 2032834200
Employees
79
Web
https://www.veronapharma.com